Abstract
Hepatocyte growth factor (HGF) plays a plethora of roles in the progression of many invasive and metastatic cancers. The interaction between tumour cells and their surrounding stromal environment remains a crucial factor governing tumour invasion and metastasis. HGF is primarily synthesised by stromal fibroblasts as an inactive precursor known as pro-HGF. A number of proteases have demonstrated the ability to convert pro-HGF into the biologically active form of HGF, although the two main factors responsible are HGF activator (HGFA) and matriptase. The HGF activation inhibitors (HAI-1 and HAI-2) are two novel Kunitz-type serine protease inhibitors that regulate HGFA and matriptase activity to govern the influence of HGF within the body. Deregulation of HAI expression can lead to shift in the HGF activation/inhibition balance ratio in favour of enhanced HGF production. Therefore, these HGF activation inhibitors may have a direct bearing on cancer invasion and metastasis. This review examines the accumulating evidence on the emerging role and therapeutic potential of HAI-1 and HAI-2 in cancer.
Keywords: Hepatocyte growth factor, matriptase, HGF activator, HGF inhibitor, HAI-1, HAI-2, prognosis
Anti-Cancer Agents in Medicinal Chemistry
Title: Hepatocyte Growth Factor Activation Inhibitors – Therapeutic Potential in Cancer
Volume: 10 Issue: 1
Author(s): Christian Parr, Andrew J. Sanders and Wen G. Jiang
Affiliation:
Keywords: Hepatocyte growth factor, matriptase, HGF activator, HGF inhibitor, HAI-1, HAI-2, prognosis
Abstract: Hepatocyte growth factor (HGF) plays a plethora of roles in the progression of many invasive and metastatic cancers. The interaction between tumour cells and their surrounding stromal environment remains a crucial factor governing tumour invasion and metastasis. HGF is primarily synthesised by stromal fibroblasts as an inactive precursor known as pro-HGF. A number of proteases have demonstrated the ability to convert pro-HGF into the biologically active form of HGF, although the two main factors responsible are HGF activator (HGFA) and matriptase. The HGF activation inhibitors (HAI-1 and HAI-2) are two novel Kunitz-type serine protease inhibitors that regulate HGFA and matriptase activity to govern the influence of HGF within the body. Deregulation of HAI expression can lead to shift in the HGF activation/inhibition balance ratio in favour of enhanced HGF production. Therefore, these HGF activation inhibitors may have a direct bearing on cancer invasion and metastasis. This review examines the accumulating evidence on the emerging role and therapeutic potential of HAI-1 and HAI-2 in cancer.
Export Options
About this article
Cite this article as:
Parr Christian, Sanders J. Andrew and Jiang G. Wen, Hepatocyte Growth Factor Activation Inhibitors – Therapeutic Potential in Cancer, Anti-Cancer Agents in Medicinal Chemistry 2010; 10 (1) . https://dx.doi.org/10.2174/1871520611009010047
DOI https://dx.doi.org/10.2174/1871520611009010047 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Melatonin, Immune Function and Cancer
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Diazenyl Derivatives and their Complexes as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry The Transcriptome in Blood: Challenges and Solutions for Robust Expression Profiling
Current Molecular Medicine Meet Our Editorial Board Member
Combinatorial Chemistry & High Throughput Screening Prospects of Primary Ovarian Insufficiency Patient-Specific Pluripotent Stem Cells for Disease Modeling and Clinical Impacts
Current Women`s Health Reviews Bugs and Drugs: Oncolytic Virotherapy in Combination with Chemotherapy
Current Pharmaceutical Biotechnology The Warburg Effect on Cancer Cells Survival: The Role of Sugar Starvation in Cancer Therapy
Current Reviews in Clinical and Experimental Pharmacology Editorial: Stay in Excellence
Current Molecular Medicine Bioinformatic Analysis Reveals Key Genes and Pathways in Aging Brain of Senescence-accelerated Mouse P8 (SAMP8)
CNS & Neurological Disorders - Drug Targets Platelet Turnover in Atherothrombotic Disease
Current Pharmaceutical Design Chalcones Incorporated Pyrazole Ring Inhibit Proliferation, Cell Cycle Progression, Angiogenesis and Induce Apoptosis of MCF7 Cell Line
Anti-Cancer Agents in Medicinal Chemistry Dendrimer-Curcumin Conjugate: A Water Soluble and Effective Cytotoxic Agent Against Breast Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Future Approaches for Treating Hematologic Disease
Current Pharmaceutical Biotechnology Electro-Organic Synthesis of New Esculetin Derivatives Based on 1,6-Conjugate Addition
Current Organic Chemistry The Potential of Microalgae for the Production of Bioactive Molecules of Pharmaceutical Interest
Current Pharmaceutical Biotechnology Evaluation of Cell-detaching Effect of EDTA in Combination with Oxaliplatin for a Possible Application in HIPEC After Cytoreductive Surgery: A Preliminary in-vitro Study
Current Pharmaceutical Design Patent Selections
Recent Patents on Anti-Cancer Drug Discovery The Tumor Suppressor Gene ARF as a Sensor of Oxidative Stress
Current Molecular Medicine Mesenchymal Stem Cells for Anti-Cancer Drug Delivery
Recent Patents on Anti-Cancer Drug Discovery Opposing Functions for the Wilms Tumor Protein 1 (WT1) in Tumorigenesis
Current Pediatric Reviews